JAGSNPHARMPharmaceuticals
Jagsonpal Pharmaceuticals Ltd — Cash Flow Statement
₹184.03
+0.05%
Jagsonpal Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Business Purchase And Sale | -93.66 Cr | 0.00 | — | — | — |
| Purchase Of Business | -93.66 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | 35.37 Cr | -0.25 Cr | 0.98 Cr | -0.47 Cr | — |
| Purchase Of PPE | -0.35 Cr | -0.25 Cr | -0.32 Cr | -1.05 Cr | — |
| Operating Cash Flow | 55.30 Cr | 35.17 Cr | 46.66 Cr | 6.91 Cr | — |
| Taxes Refund Paid | -8.14 Cr | -8.51 Cr | -7.28 Cr | -6.87 Cr | — |
| Change In Working Capital | 5.52 Cr | 5.54 Cr | 9.50 Cr | -11.46 Cr | — |
| Change In Other Current Liabilities | 4.48 Cr | 3.19 Cr | 2.36 Cr | -1.11 Cr | — |
| Change In Other Current Assets | 0.75 Cr | -3.35 Cr | 6.26 Cr | -5.64 Cr | — |
| Change In Payable | 2.14 Cr | -8.98 Cr | -1.96 Cr | -1.07 Cr | — |
| Change In Inventory | 10000.00 | 5.31 Cr | 8.69 Cr | -0.02 Cr | — |
| Change In Receivables | -2.23 Cr | 9.15 Cr | -5.56 Cr | -2.96 Cr | — |
| Other Non Cash Items | -26.37 Cr | -7.78 Cr | -0.24 Cr | -1.26 Cr | — |
| Stock Based Compensation | 6.80 Cr | 13.31 Cr | 8.77 Cr | 0.00 | — |
| Provisionand Write Offof Assets | -0.30 Cr | 0.71 Cr | 0.40 Cr | -0.45 Cr | — |
| Depreciation And Amortization | 8.13 Cr | 1.66 Cr | 1.18 Cr | 1.53 Cr | — |
| Depreciation | 8.13 Cr | 1.66 Cr | 1.18 Cr | 1.53 Cr | — |
| Net Income From Continuing Operations | 69.86 Cr | 29.87 Cr | 34.81 Cr | 26.64 Cr | — |
| Sale Of PPE | 35.72 Cr | 0.00 | 1.30 Cr | 0.58 Cr | — |
| Free Cash Flow | 54.95 Cr | 34.92 Cr | 46.34 Cr | 5.87 Cr | — |
| Issuance Of Capital Stock | 3.39 Cr | 5.63 Cr | 0.00 | — | — |
| Capital Expenditure | -0.35 Cr | -0.25 Cr | -0.32 Cr | -1.05 Cr | — |
| End Cash Position | 11.21 Cr | 12.76 Cr | 11.05 Cr | 22.53 Cr | — |
| Beginning Cash Position | 12.76 Cr | 11.05 Cr | 22.53 Cr | 58.94 Cr | — |
| Changes In Cash | -1.54 Cr | 1.71 Cr | -11.47 Cr | -36.42 Cr | — |
| Financing Cash Flow | -11.70 Cr | -8.91 Cr | -0.46 Cr | -17.55 Cr | — |
| Interest Paid Cff | -0.96 Cr | -0.81 Cr | -0.41 Cr | -0.28 Cr | — |
| Cash Dividends Paid | -13.23 Cr | -13.10 Cr | — | -10.48 Cr | -2.62 Cr |
| Net Common Stock Issuance | 3.39 Cr | 5.63 Cr | 0.00 | -1.54 Cr | — |
| Common Stock Issuance | 3.39 Cr | 5.63 Cr | 0.00 | — | — |
| Investing Cash Flow | -45.15 Cr | -24.55 Cr | -57.67 Cr | -25.78 Cr | — |
| Interest Received Cfi | 7.84 Cr | 7.37 Cr | 3.43 Cr | 1.55 Cr | — |
| Net Investment Purchase And Sale | 5.30 Cr | -31.67 Cr | -62.08 Cr | -26.86 Cr | — |
| Sale Of Investment | 260.93 Cr | 103.74 Cr | 43.82 Cr | — | — |
| Purchase Of Investment | -255.63 Cr | -135.41 Cr | -105.89 Cr | -28.45 Cr | — |
| Gain Loss On Sale Of PPE | — | 0.00 | -0.36 Cr | -0.09 Cr | 0.00 |
| Repayment Of Debt | — | — | 0.00 | -6.79 Cr | — |
| Net Other Financing Charges | — | — | -0.32 Cr | — | — |
| Net Issuance Payments Of Debt | — | — | 0.00 | -6.79 Cr | — |
| Net Short Term Debt Issuance | — | — | 0.00 | -6.79 Cr | — |
| Short Term Debt Payments | — | — | 0.00 | -6.79 Cr | — |
| Net Long Term Debt Issuance | — | — | 0.00 | -6.79 Cr | — |
| Long Term Debt Payments | — | — | 0.00 | -6.79 Cr | — |
| Net Other Investing Changes | — | — | -10000.00 | — | — |
| Gain Loss On Investment Securities | — | — | -0.15 Cr | -1.14 Cr | 0.25 Cr |
| Effect Of Exchange Rate Changes | — | — | — | 0.00 | 0.00 |
| Deferred Tax | — | — | — | 0.33 Cr | -1.23 Cr |
| Amortization Cash Flow | — | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jagsonpal Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.